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ABSTRACT : Surgical outcome for carcinoma of the esophagus is not yet 
satisfied. The reasons are based on the delay in diagnosis. As a matter of fact a 
complaint of dysphagia means advanced stage of cancer. In general, such a patient 
suffers from poor nutritional condition which relates to restriction of oral intake, 
and this disease frequently affects the aged people. Furthermore, anatomical 
specificity of the lack of the serosal layer is likely affected by carcinoma outside the 
wall of the esophagus. And rich lymphatic flow tends to constitute lymphatic 
metastasis anywhere in the longitudinal direction. 
   In order to improve surgical results for carcinoma of the esophagus an impor-
tant access to the treatment is to inhibit the growth of recurrent cancer cells effectively. 
    In this series, experience with recurrent carcinoma of the esophagus was 
clinically analyzed to search for a better management.
         PATIENTS 
 Seventeen patients who received the treat-
ment for recurrence after surgical intervention 
for carcinoma of the esophagus are eligible for 
this study during the ten years period from 
January 1978 to December 1987 in the Firtst 
Department of Surgery, Nagasaki University 
School of Medicine. 
 These 17 cases comprise of 16 men and one 
woman, aged from 38 to 69 years old. 
 According to the locations of primary le-
sions. it indicated carcinomas in Ph Ce and 
Ei are liable to recur more often than those in 
other sites of the esophagus. However, recur-
rences were seen in anywhere despite a limited 
number of patients. Most of recurrent pa-
tients contained advanced cancer stages more 
than stage II. (Table 1) 
 The depth of cancer infiltration varied from 
the submucosal layer to outside of the advanti-
tia, most of recurrent patients indicated 
cancer infiltrations of more than a 1. In nodal 
involvement, recurrent patients had extensive 
node metastases of more than n 1. The time
         Table 1. Clinical and pathological features 
location stage classification depth of cancer node metastasis 
Ph, Ce 6 0 1 sm 2 n0 3 
Iu 2 I 0 mp 3 n1 4 
Im 3 II 2 al 3 n2 5 
Ei 6 III 8 a2 7 n3 3 
     17 IV 6 a3 2 n4 2
                 17 17 17
duration from the initial operation to appear-
ance of recurrence ranged from one month to 
3 years and 9 months, in most cases it was 
within 6 months of disease-free interval. 
 The locations of recurrent lesions were 
local, and the mediastinum including the lung, 
trachea, pleura in 7, nodal involvement in the 
neck in 6 and liver metastasis in 3. There were 
recurrences in the anastomotic sites in 4, leav-
ing a question about the extent of resection. 
(Table 2)
     Table 2. Location of metastasis 
neck, supraclavicular nodes 7 cases 
local anastomotic 6 
mediastinum, tracheobronchus 3 
lung, pleura 4 
liver 3 
rib 2
 The treatments for recurrence were listed in 
Table 3. There are few cases in whom surgery 
is indicative. In only 2 cases, surgery of neck 
dissections was applied. The main treatments 
were composed of administration of anticancer 
drugs. irradiation and BRM treatment. A few 
patients received laser therapy, hypertheramia 
and TAE and lipiodolization for patients with 
liver metastases. Simultaneous metastases
     Table 3. Treatment for recurrence 
irradiation 7 cases 




 OK432 intrathoracic 1 
 MMC lipidolization 1 
 laser 1
                   Table 4. Patients with recurrence evaluable for treatment 
             disease combined recurr therapy for strvival postop. age sex location staging therapy D.F.I sites recurrence effect from recc. survival 
71 M Im III Rad. RP 20M neck node Rad. 50Cy (PR) 8M 28M 
               a2, nl 
56 M Ei >II Rad. PO 13M liver rib CDDP (PD) 3M 16M 
             al, n2 pleura, lung PEP 3 courses 
52 M PhCe III Rad. PO 1M anastomosis hyperthermia (PD) 4M 5M 
            a2, n1 CDDP+ PEP 
70 M PhCe III CDDP X PEP 1 M anastomosis Rad. (PD) 5 M 6 M 
                a2, nl 
79 M Iu IV (-) 3M supracl. nodes Rad. (CR) 5M 8M 
             a2, n4 neck dissection 
                                                     laser 
49 M ImEi II Rad. RP 11M mediastinum CDDP+ PEP (NC) 5M 16M 
            al, nl FT207 trachea 
                PRK rib 
54 M Eilm IV Rad. RP 11M lung CDDP (CR) 17M 28M 
            a2, n4 MMC 30mg PEP 3 courses 
                PEP 100mg OK430 
                FT207 
               PSK 
50 M Im 1II Rad. PO 10M r-bronchus OK432 (PD) 7M 17M 
            a2, n2 OK432 neck nodes FT207 
                                       lung laser 
56 M Ei IQ CDDP+ PEP 12M liver CDDP (PD) 2 M 14M 
               mp, n2 
49 M Ce 0 Rad. PO 45M neck nodes Rad. 50Cy (PR) 9M 54M 
            sm, nO MMC PEP 
                                        OK432
into two or three organs occurred in 5 cases 
who had a relative long period of disease free 
interval. However, no remarkable effectiveness 
was observed in most patients with PD in 11 
and NC in 1 (Table 4 ). Although there were 
significant effects which were regarded as 
CR in 2 and PR in 3, including the patients 
who underwent neck dissection and irradiation 
for cervical node metastasis in 2 and recieved 3 
courses of a combination therapy of anticancer 
drugs, CDDP, PEP OK-432 for bilateral lung 
metastasis. These facts are suggestive of 
significant anticancer effects for patients in 
whom sufficient adjuvant therapy including 
anticancer drugs might be given. The prognosis 
for recurrence was pessimistic and all but one 
case who survived 1 year and 7 months died 
within 1 year. Eleven died within 6 months and 
the other 5 survived from 6 months to 1 year, 
showing PR in 2. However, even in 3 cases 
who demonstrated PD, they survived more 
than 6 months. The effectiveness of anticancer 
drugs was not in proportion to elongation of 
the survival time.
        DISCUSSION 
 Surgical outcome for carcinoma of the 
esophagus has been improved and the opera-
tive death went down to less than 5 per cent. 
However, it is no doubt that carcinoma of the 
esophagus is one of the diseases that shows 
poor prognosis. 
 Needless to say, it is necessary that early 
detection and early treatment are the most 
important clue to improve surgical outcome. 
Even in patients with recurrence, aggressive 
treatment was required for prolongation of 
the survival time. 
 Recently potent anticancer drugs such as 
CDDP, VP-16 and VCR have been widely used 
and their good effects were expected. Local 
treatments by the use of laser, 4) 5) hyper-
thermia 6 ) and local irradiation 7 ) are recom-
mended for combination therapy. 
 In fact, recurrence comprises of hematoge-
nous and lymphatic metastases in most 
patients with recurrence, and the patients 
with local metastasis alone were quite few. 
Furthermore, application of surgery for
patients with recurrence was limited. In this 
series, surgery was indicated for only patients 
with nodal involvement in the neck. 
 As a matther of fact, when recurrent sign 
appears clinically, carcinoma used to be extend-
ed with a wide spreading in the liver, bone and 
lung. It is assumed that modes of recurrence 
may be altered by aggressive curative opera-
tion in combination with more extensive 
bilateral neck dissection,. and nodal involve-
ment at recurrence may be depressed. It is 
generally accepted that carcinoma of the 
esophagus rapidly extends with multiple 
distant metastases. 8) Therefore, it is rare in 
frequency that surgery is applied in the 
treatment for patients with recurrence and the 
surgical outcome is poor. 9) 
 It is obvious that the lung and the liver tend 
to be affected by blood-borne metastasis. 9) In 
this study, it was confirmed that bone 
metastasis also is indispensable lesions that 
occurred more often. 10) 
 Recurrence of carcinoma of the esophagus 
more frequently involves cervical lymphnodes 
through lymphatic spreading as well as the 
lung and liver through blood-borne metastasis. 
Therefore, it is difficult to manage the 
patients with recurrence. It is recommended 
that management at recurrence should be done 
for multiple lesions, which are composed of 
nodal involvement and distant metastasis. 
Combination therapy with potent anticancer 
drugs such as CDDP, VP- 16, ADM and VCR 
should be prescribed. 
  In this series, the treatment at recurrence 
was not effective in elongating the survival 
time and in improving performance status 
even if combination of potent anticancer 
drugs with laser, hyperthermia and TAE had 
been applied. On the basis of a result of this 
study, potent adjuvant therpy prior to an 
apperance of recurrence is required for the 
improvement of surgical outcome in the 
treatment of carcinoma of the esophagus.
        CONCLUSION 
 The treatments for patients with recurrence 
were analyzed in the 17 patients on the basis 
of a review of our own experience.
1 ) The locations of recurrence were node 
involvement in the neck in 7, anastomotic site 
in 6, mediastinum, trachea and bronchi in 3, 
the lung and pleura in 4, the liver in 3, the rib 
in 2 respectively. 
2 ) The disease-free interval ranged from 1 
month to 45 months with a mean of 9.7 
months. In most of them (82.3%), recurrences 
took place within 1 year after surgical 
resections. 
3) The treatments for patients with recurren-
ce were not valid because of multiple lesions 
except for surgery on patients with nodal 
involvement in the neck. 
4) To improve surgical outcome for patients 
with recurrence, it is recommended that 
available and effective treatments be continu-
ed prior to appearance of recurrence. In addi-
tion, it is emphasized that the treatments at 
recurrence was not so effective , even if they 
are potent and combined therapy is prescribed.
